Skip to main content
Menu
Revvity logo
Contact us
HK
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States

Bridging the gap...

from research and discovery...

from research and discovery...

img-discovery-icon.png

Discovery

img-discovery.png
img-discovery-icon.png

Antibodies & tools for target & hit discovery

img-discovery-icon.png

Preclinical Development

img-clinical-development.jpg
img-preclinical-development-icon.png

Assays & platforms for lead & process development

img-clinical-development-icon.png

Clinical Development

img-market-approval.jpg
img-clinical-development-icon.png

Stratification and data management solutions

img-market-approval-icon.png

Market Approval

img-preclinical-development.jpg
img-discovery-icon.png

Solutions supporting product quality and efficacy

img-screening-icon.png

Screening

https://resources.revvity.com/images/img-screening.jpg
img-screening-icon.png

Screening tools for early detection

img-diagnostics-and-monitoring-icon.png

Diagnostics & Monitoring

img-diagnostics-and-monitoring.jpg
img-diagnostics-and-monitoring-icon.png

End-to-end solutions for specialty diagnostics

to diagnostics and cure.

img-mini-elisa-plate-reader-872x872.png

50% OFF Mini ELISA Plate Reader™

Streamline your ELISA workflow with BioLegend’s Mini ELISA Plate Reader™. T&Cs apply.

Visit BioLegend.com
img-nav-promo-hello10.png

SAVE 10% on your first online order

Use code HELL10 at checkout T&Cs apply.

Learn more
AssayMate™ liquid handler

AssayMate™ liquid handler

Automation performance, now for labs of any size.

Learn more

Industries we serve

img-academia-icon.svg
Academia
1.5K

new antibodies, kits, and reagents introduced annually for life science research.

27K

peer-reviewed publications using our In Vivo imaging systems.

5,650

published citations of Dharmacon™ reagents in 2023.

img-pharma-biotech-icon.svg
Pharma / Biotech
94%

of the top 50 pharmaceutical companies worldwide use our innovative solutions.

1,700

no-wash immunoassays and reagents for efficient screening.

2M+

scientists across pharma, biotech, and academia utilize our software solutions.

150

licensees across Revvity's technology and licensing organization.

img-clinical-laboratories-icon.svg
Clinical Laboratories
33M+

babies screened annually for life-threatening disorders with Revvity technologies.

85M+

blood samples analyzed with EUROIMMUN solutions to identify autoimmune disorders.

75M+

individuals tested for COVID-19 virus with Revvity tests.

20M+

individuals tested for latent TB infection with the T-SPOT.TB test since 2002.

img-healthcare-professionals-icon.svg
Healthcare Professionals
85

newborn lives saved daily.

550+

mentions of the T-SPOT.TB test in peer reviewed publications.

75+

years of innovation in maternal, fetal, and neonatal health.

300M+

genomic tests performed to detect rare inherited diseases and hereditary cancers.

img-cros-icon.svg
CROs
Top 10

CROs use our reagents, instruments and software to support their clients in commercializing their discoveries.

Top 25

CDMOs utilize our proven life science technologies to support their clients in every part of their commercialization journey.

safety-efficacy-512x288.jpg

Life Sciences

Revvity offers comprehensive life science solutions, technologies, and services, covering workflows from discovery to cure. We revolutionize biomedical research with a focus on translational multi-omics, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and more.

Cell and Gene Therapy
Biologics
Small Molecule Drug Discovery
Genomic Analysis
Protein Analysis
Cell Analysis
Instruments and Automation
View all

Popular reagent brands

BioLegend™
AlphaLISA™ and SureFire®
HTRF™
Dharmacon™

Popular instrument brands

Opera Phenix™
EnVision™
IVIS™
Fontus™
Cellometer™
Omni Bead Ruptor Elite™
LabChip™
Licensing and contract services

Licensing and Contract Services

Collaborate with our skilled scientists and experts to reach your goals sooner. Our range of contract services supports preclinical oncology drug discovery, viral vector manufacture, omics discovery, the development of genetic disease treatments, and clinical genetic testing. We also provide novel licensable technologies for gene expression, editing, and delivery to help you bring safer, more effective treatments to patients.

Preclinical Services
Viral Vector Engineering
Novel Technologies
Revvity Omics Services
Clinical Services
ViaCord®
View all

Contract services brands

OncoSignature™
CNGnome™
StepOne™

Licensing brands

CHOSOURCE™
LentiBOOST™
Pin-point™
Reproductive health

Reproductive Health

Our innovative laboratory solutions enhance reproductive health across all stages. Our cutting-edge research solutions drive innovation in reproductive health science, while our advanced screening technologies enable early detection and timely interventions, ultimately empowering improved outcomes globally.

Maternal and Prenatal Testing
Newborn Screening
Cell-free DNA Analysis
Pre-eclampsia Management
Pregnancy-related Infections
View all

Popular brands

Vanadis™
GSP™
EONIS™
EVOYA™
Immunodiagnostics

Immunodiagnostics

Our specialty portfolio delivers innovative, end-to-end solutions for identifying and investigating a broad range of immune system disorders. We integrate cutting-edge technologies, such as immunoassays, molecular assays, automation, and advanced software - to enable seamless workflow integration, ultimately expanding research and testing for these highly complex diseases.

Infectious Diseases
Allergy
Autoimmunity
Endocrinology
Neurodegeneration
Pathogen Detection
T-SPOT Technology
View all

Popular brands

T-SPOT™
EUROIMMUN
chemagic™
IDS

Featured Blogs

Study reveals multifaceted roles of β-arrestins in GPCR internalization, including GLP-1R
Study reveals multifaceted roles of β-arrestins in GPCR internalization, including GLP-1R.

Study reveals multiple mechanisms regulating GPCR internalization, challenging the traditional view that β-arrestins are universally required for GPCR endocytosis.

Addressing technical barriers in primary T cell research
Addressing technical barriers in primary T cell research.

Discover how advanced lentiviral delivery and functional genomics tools overcome barriers in primary T cell research to accelerate autoimmune studies

From Policy to Practice: What FDA's 2025 Direction Means for Your Precision Medicine Pipeline
From policy to practice: what FDA's 2025 direction means for your precision medicine pipeline.

This blog discusses the implications of the FDA’s “plausible mechanism pathway” guidance for gene therapy developers and precision therapy.

Enhancing CAR NK-cell research with chemically defined serum-free culture solutions
Enhancing CAR NK-cell research with chemically defined serum-free culture solutions.

Discover how chemically defined serum-free solutions optimize CAR NK-cell culture, enabling expansion, phenotyping, and cytotoxicity analysis

cas9 blog thumbnail
Programmable depletion with CRISPR–Cas9: what DASH is, why it works, and where to use it.

Learn how DASH uses CRISPR-Cas9 RNPs to remove rRNA, globin, adapter dimers, and mtDNA from NGS libraries. Protocol tips, guide design, and use cases.

extraction blog thumbnail
What to consider when scaling tissue lysis workflows for multi-analyte DNA/RNA workstreams.

Dual DNA and RNA extraction using bead mill homogenizers for high-throughput, well-plate tissue lysis workflows. Scalable, reproducible, and cryogen-free lysis.

variant calling blog thumbnail
Variant calling through bulk RNA-seq is growing up: implications for oncology introduction.

Learn how VarRNA classifies artifact, germline, and somatic variants from bulk RNA-Seq and what it means for oncology research and assay setup.

image blog plasma thumbnail
Next GeneSiS: cfDNA sequencing outperforms blood culture in sepsis.

Prospective multicenter data show plasma microbial cfDNA sequencing detects pathogens more often than blood culture and can inform stewardship decisions.

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.

Illuminator - About company

Our sustainable impact

img-our-esg-impact.jpg

Advancing science and sustainability.

Explore more

News

Revvity to Present at J.P. Morgan Healthcare Conference
December 18, 2025
|
Press release
View more
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery
December 16, 2025
|
Press release
View more
Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy
November 10, 2025
|
Press release
View more
View all

Careers

img-careers.png

Find your future at Revvity

Join Revvity's team of approximately 11,000 global colleagues and help us push boundaries in pursuit of better human health.

Careers

Investors

img-investors.jpg

Stay informed on the company's financial performance.

Investors
line

How can we help you?

We are here to answer your questions.

Contact us
Contact us
Request product information, quote/price request
Request product information
Order, shipping, invoice or service contact inquiry
Order, shipping, service contact inquiry
Instrument service request
Instrument service request
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.